History has shown us how government-imposed prices end badly for consumers. We rarely see the intended results last for long, while their side effects have enormous consequences. President Donald Trump is now discussing foreign reference pricing, paying little mind to a chorus of economic experts, innovators, and seniors who are concerned that those policies will do more harm than good. Ultimately, the more that the administration and Congress layer price controls on our healthcare system, the more they risk the health and well-being of seniors.
In recent days, the administration has discussed the “most favored nation” policy, which will be far-reaching and damaging to patient access and competition in the healthcare market. With this proposal, drug prices would become tied to those in other nations, such as Canada and European countries. The issue here is that many of those nations have single-payer systems where the government single-handedly determines the drug prices. Moreover, many of these countries use discriminatory “value” standards that devalue newer medicines and discriminate against the elderly and people with disabilities. Any efforts to tie our drug prices to these nations will only effectively import their pricing mechanisms, and the societal values and harms that come with them, into our market.